INVESTOR ALERT: Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Ra Medical Systems, Inc.

NEW YORK--(BUSINESS WIRE)-- The law firm of Kirby McInerney LLP is investigating potential claims against Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED). This investigation concerns whether Ra Medical has violated federal securities laws and/or engaged in other unlawful business practices.

In September 2018, Ra Medical completed its initial public offering (“IPO”), issuing approximately 4.5 million shares of common stock priced at $17.00 per share. On March 14, 2019, the Company revealed that its fourth quarter 2018 financial results had been negatively impacted by issues related to the hiring and training of qualified sales personnel and certain production limitations. On this news, Ra Medical’s stock price fell $2.14 per share, approximately 32.6%, to close at $4.43 per share on March 15, 2019. As of market close on May 28, 2019, the stock price was $3.60.

If you acquired Ra Medical securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005834/en/

Kirby McInerney LLP

Thomas W. Elrod, Esq., (212) 371-6600

[email protected]

www.kmllp.com

Source: Kirby McInerney LLP